1. Toyokawa G, et al. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev 2015;34(4):797–805.
2. Soria JC, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged nonsmall-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389(10072):917–929.
Takeda Pharma AG, Huobstrasse 16, 8808 Pfäffikon; Tel. 055 451 52 00, Fax 055 451 52 60, www.takeda.ch